Separately, Canaccord Genuity Group cut their price target on Think Research from C$3.00 to C$2.00 and set a “buy” rating for the company in a report on Tuesday, May 3rd.
THKKF remained flat at $0.52 during trading on Wednesday. Think Research has a 1-year low of 0.00 and a 1-year high of 1.90.
Think Research Corp., an investment holding company, gathers, develops, and delivers knowledge-based Software-as-a-Service solutions for the health care industry in Canada, the United States, and internationally. The company's products portfolio comprises COVID-19 tools; order sets that structures clinical pathway at the point of care; Progress Notes, which helps frontline clinical teams to align their documentation in a standardized digital note shared across all team members; eReferrals that allows physicians to find and refer specialists directly from EMR systems; VirtualCare, which allows clinicians and allied health professionals to replace in-person appointments with virtual visits; and eforms, a real-time analytics to track resident volumes, signature adherence, and compliance, as well as decision support tools for seniors living in long-term care and retirement homes.
- The Analysts Like The Fit Of Victoria’s Secret & Co
- Ambarella Is A Buy For Patient Investors
- Don’t Bet On A Big Rebound For Salesforce.com Stock
- 3 Specialty Retailers with Special Upside
- Is Roku (NASDAQ: ROKU) Bottoming Out?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Think Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Think Research and related companies with MarketBeat.com's FREE daily email newsletter.